-
Mashup Score: 0
Prostate radiotherapy added to intensified systemic therapy for de novo low-volume mCSPC decreases the risk of radiographic disease progression.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Erdafitinib improves survival vs chemotherapy in patients with metastatic urothelial carcinoma and select FGFR alterations who were previously treated with immune checkpoint inhibitors, a phase 3 trial suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Combination pembrolizumab and axitinib continues to show superior efficacy to sunitinib in advanced clear cell renal cell carcinoma, according to updated data from a phase 3 trial.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Addition of MDT to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer - 10 month(s) ago
This randomized clinical trial examines whether the addition of metastasis-directed therapy (MDT) to intermittent hormone therapy in men with oligometastatic prostate cancer improves progression-free survival.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Risk for Second Primary Cancers by Type of Radiation Therapy in Older Men With Prostate Cancer - 11 month(s) ago
This cohort study evaluates whether radiotherapy type (intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy) was associated with second primary cancer risk among older men treated for prostate cancer.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Association of Second-Generation Antiandrogens With Cognitive and Functional Toxic Effects - 11 month(s) ago
This systematic review and meta-analysis examines the risk of toxic effects associated with second-generation antiandrogens administered to men with prostate cancer in randomized clinical trials.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer - 12 month(s) ago
This systematic review and meta-analysis investigates the comparative effectiveness of triplet therapy vs androgen pathway inhibitors doublet therapy for patients with heterogeneous metastatic castration-sensitive prostate cancer.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0MRI-Guided vs CT-Guided Stereotactic Body Radiotherapy for Patients With Prostate Cancer - 1 year(s) ago
This randomized clinical trial assesses genitourinary toxic effects after magnetic resonance imaging (MRI)–guided vs computed tomography (CT)–guided stereotactic body radiotherapy for prostate cancer.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7
This randomized clinical trial examines whether the addition of metastasis-directed therapy (MDT) to intermittent hormone therapy in men with oligometastatic prostate cancer improves progression-free survival.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Investigating the racial gap in prostate cancer screening with prostate-specific antigen among younger men from 2012 to 2020 - 1 year(s) ago
AbstractBackground. The United States Preventive Services Task Force recommended against prostate-specific antigen (PSA) screening in 2012, which was modified i
Source: OUP AcademicCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Adding prostate radiotherapy to intensified systemic therapy improved rPFS in patients with de novo low-volume mCSPC in the phase 3 PEACE-1 trial. #ASCO23 #gucsm #pcsm https://t.co/a2q4IaINYI